The effects of psychedelics on attention-deficit and hyperactivity disorder – a systematic review
Acta Neuropsychiatrica · 2026 · 38
DOI: 10.1017/neu.2026.10088 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Neuropsychiatrica, online erschienen am 10.06.2026. Verfasst von Helerin Raikkerus und 3 weiteren Autor:innen. Beteiligte Einrichtung: Helsinki University Hospital, Helsinki, Finland. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Attention-deficit and hyperactivity disorder (ADHD) is a prevalent neuropsychiatric disorder. Recently, psychedelics have become of interest regarding developing treatment options for ADHD. The aim of this systematic review is to find all studies from the APA PsychInfo and MEDLINE databases, where psychedelics have been used for ADHD and assess whether further clinical studies are warranted.
Methods
APA PsychInfo and MEDLINE were searched on the 20th of August 2025 for studies discussing ADHD and lysergic acid diethylamide (LSD) or psilocybin or dimethyltryptamine (DMT) or mescaline or phencyclidine or 3,4-methylenedioxymethamphetamine (MDMA) or ketamine. Primary research articles in English where the effects of the psychedelics mentioned on ADHD in humans were included.
Results
N = 1023 results were identified. Six studies were included – one randomised controlled trial (RCT) finding no statistically important difference compared to placebo, three cross-sectional studies where respondents reported positive effect of psychedelics and one where the statistically important improvement was measured by the Child Bipolar Questionnaire. In addition, one case study, where both, depressive symptoms and functioning improved with ketamine.
Conclusions
There is not sufficient evidence to give recommendations on psychedelic use for ADHD. In addition, it is not known whether patients, whose depressive symptoms have responded positively to ketamine, have also had ADHD. Also, no research was found on how psychedelics affect patient subgroups with different etiopathology causing their symptoms. Although only six studies filled the inclusion criteria, they bring out valuable implications for further research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Helsinki University Hospital, Helsinki, Finland.
- Department of Child and Adolescent Psychiatry, King's College London, United Kingdom.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Centre for Psychiatry Research, Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.
- Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
- Neuroscience Center, University of Helsinki, Helsinki, Finland.
ORCID-Profile: Helerin Raikkerus
Zitieren
APA
Raikkerus, H., Bujour, A., Kennedy, M., & Tiihonen, J. (2026). The effects of psychedelics on attention-deficit and hyperactivity disorder – a systematic review. Acta Neuropsychiatrica, 38. https://doi.org/10.1017/neu.2026.10088
Vancouver
Raikkerus H, Bujour A, Kennedy M, Tiihonen J. The effects of psychedelics on attention-deficit and hyperactivity disorder – a systematic review. Acta Neuropsychiatrica. 2026;38. doi:10.1017/neu.2026.10088
BibTeX
@article{Raikkerus2026,
author = {Raikkerus, Helerin and Bujour, Andrea and Kennedy, Mark and Tiihonen, Jari},
title = {The effects of psychedelics on attention-deficit and hyperactivity disorder – a systematic review},
journal = {Acta Neuropsychiatrica},
year = {2026},
volume = {38},
doi = {10.1017/neu.2026.10088}
}
EUVIMED